Another advantage of HB-19 over traditional anti-cancer drugs is its capacity to bind surface nucleolin in an irreversible manner under physiological conditions [26], making the half-life of tissue associated HB-19 much longer compared to that of any other cancer drug [15]. Here, NUCLEOLIN is linked to cancer.